Volume 15, Issue 1 supplement

Search all Indian Journal of Gynecologic Oncology articles

December 2017

Controversies in Gynecological Cancers

Filter by

Volume:

Sort by

Date published:

New to old Old to new

12 articles in this issue

Controversies in Gynaecologic Oncology
Amita Maheshwari
Sudeep Gupta
Editorial 18 December 2017 Pages: 1 - 2
Antiangiogenic Therapy Should be Considered Standard Treatment in the Adjuvant Therapy of Epithelial Ovarian Cancer
Senthil J. Rajappa
Controversies in Gynecological Cancers 18 December 2017 Pages: 3 - 7
Ovarian Cancer: Bevacizumab as Adjuvant Treatment—Not Yet
Amit Agarwal
CONTROVERSIES IN GYNECOLOGICAL CANCERS 18 December 2017 Pages: 9 - 10
Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer
Shigeki Kusamura
Snita Sinukumar
Marcello Deraco
Controversies in Gynecological Cancers 18 December 2017 Pages: 11 - 20
There is Currently no Role of HIPEC in Epithelial Ovarian Cancer in Routine Clinical Practice
Yogesh Kulkarni
P. Kalyan
CONTROVERSIES IN GYNECOLOGICAL CANCERS 18 December 2017 Pages: 21 - 25
Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer
Lindsay J. Wheeler
Saketh Guntupalli
Controversies in Gynecological Cancers 18 December 2017 Pages: 27 - 30
Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer
Shona Nag
Snita Sinukumar
Sujai Hegde
Controversies in Gynecological Cancers 18 December 2017 Pages: 31 - 36
Systematic Retroperitoneal (Pelvic and Para-aortic) Lymph Node Dissection Should be Routinely Performed in Patients with Clinically Early Endometrial Cancer
Manash Biswas
Controversies in Gynecological Cancers 18 December 2017 Pages: 37 - 43
Systematic Retroperitoneal (Pelvic and Para-aortic) Lymph Node Dissection Cannot be Routinely Recommended in All Patients of Clinically Early Endometrial Cancer
Bhupesh K. Goyal
Bidhan Roy
Controversies in Gynecological Cancers 18 December 2017 Pages: 45 - 48
Is There Any Difference in Platelets Indices Between Benign and Malignant Epithelial Tumors of the Ovary?
Setare Nassiri
Shahrzad Sheikh Hassani
Setare Akhavan
Controversies in Gynecological Cancers 18 December 2017 Pages: 49 - 53
Standardization of Patient Selection and Hyperthermic Intraperitoneal Chemotherapy Protocol for Peritoneal Surface Malignancy in Indian Patients
Somashekhar S. P
Ashwin K. R
Poonam Patil
Controversies in Gynecological Cancers 18 December 2017 Pages: 55 - 63
DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story
Sunu Lazar Cyriac
Amit M. Oza
Katherine Karakasis
Controversies in Gynecological Cancers 18 December 2017 Pages: 65 - 75

Volume 15, Issue 1 supplement

Controversies in Gynaecologic Oncology

Antiangiogenic Therapy Should be Considered Standard Treatment in the Adjuvant Therapy of Epithelial Ovarian Cancer

Ovarian Cancer: Bevacizumab as Adjuvant Treatment—Not Yet

Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer

There is Currently no Role of HIPEC in Epithelial Ovarian Cancer in Routine Clinical Practice

Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer

Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer

Systematic Retroperitoneal (Pelvic and Para-aortic) Lymph Node Dissection Should be Routinely Performed in Patients with Clinically Early Endometrial Cancer

Systematic Retroperitoneal (Pelvic and Para-aortic) Lymph Node Dissection Cannot be Routinely Recommended in All Patients of Clinically Early Endometrial Cancer

Is There Any Difference in Platelets Indices Between Benign and Malignant Epithelial Tumors of the Ovary?

Standardization of Patient Selection and Hyperthermic Intraperitoneal Chemotherapy Protocol for Peritoneal Surface Malignancy in Indian Patients

DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story

Navigation